Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000179619 | SCV000231893 | likely benign | not specified | 2015-02-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000870531 | SCV001012035 | likely benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002517754 | SCV003676420 | uncertain significance | Inborn genetic diseases | 2024-05-15 | criteria provided, single submitter | clinical testing | The c.9553G>A (p.G3185R) alteration is located in exon 63 (coding exon 63) of the FRAS1 gene. This alteration results from a G to A substitution at nucleotide position 9553, causing the glycine (G) at amino acid position 3185 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV000870531 | SCV005078442 | uncertain significance | not provided | 2024-03-05 | criteria provided, single submitter | clinical testing | Identified in an individual with kidney and urinary tract disease in published literature who also harbored the p.(E2195G) variant on the same allele (in cis) (PMID: 35368817); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35368817) |
Prevention |
RCV003927686 | SCV004747017 | benign | FRAS1-related disorder | 2019-08-13 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |